Ultrasight
Founded Year
2018Stage
Series B | AliveTotal Raised
$15MLast Raised
$13M | 2 yrs agoUltrasight's Product Videos
ESPs containing Ultrasight
The ESP matrix leverages data and analyst insight to identify and rank leading companies in a given technology landscape.
These companies facilitate medical diagnostic testing at the site of care delivery, forgoing the need for third-party labs or testing centers, to enable more rapid clinical decision-making. Providers use point-of-care diagnostics to reduce referrals to external providers, speed diagnosis and access to treatment, and improve emergency department efficiency.
Ultrasight named as Challenger among 10 other companies, including Included Health, Binx Health, and Visby Medical.
Compete with Ultrasight?
Ensure that your company and products are accurately represented on our platform.
Ultrasight's Products & Differentiators
UltraSight AI Guidance
UltraSight is a game changer by allowing healthcare providers to take cardiac U/S images in a wider variety of care settings at a consistent level of quality: • For the 1st time, novice users can acquire high quality cardiac U/S images with confidence; allowing accurate treatment, shift tasks to less credentialed staff, reducing costs • With real-time AI guidance, cardiac U/S can be performed in any care setting (clinics, nursing homes, rural) increasing access to advanced care • Cardiac U/S imaging takes significant effort to get diagnostic quality images. Real-time guidance instructs the user and indicates when the quality threshold has been met. • Reduce the need for repeat exams (industry: 20% non-interpretable images) • Increase reproducibility: unlike CT and MRI, U/S is a user-dependant modality. By scoring images for q
Expert Collections containing Ultrasight
Expert Collections are analyst-curated lists that highlight the companies you need to know in the most important technology spaces.
Ultrasight is included in 6 Expert Collections, including Artificial Intelligence.
Artificial Intelligence
10,459 items
This collection includes startups selling AI SaaS, using AI algorithms to develop their core products, and those developing hardware to support AI workloads.
Medical Devices
8,875 items
Companies developing medical devices (per the IMDRF's definition of "medical device"). Includes software, lab-developed tests (LDTs), and combination products. *Columns updated as regularly as possible.
Health Monitoring & Diagnostics
3,003 items
Companies developing or offering products that aid in the assessment, screening, diagnosis, or monitoring of a person's state of health/wellness. Excludes companies focused solely on fitness/sports performance
Digital Health
12,697 items
Technologies, platforms, and systems that engage consumers for lifestyle, wellness, or health-related purposes; capture, store, or transmit health data; and/or support life science and clinical operations. (DiME, DTA, HealthXL, & NODE.Health)
Health IT
8,264 items
Clinical Encounter Tech
899 items
Ultrasight Patents
Ultrasight has filed 1 patent.
The 3 most popular patent topics include:
- Medical imaging
- Medical physics
- Medical ultrasonography
Application Date | Grant Date | Title | Related Topics | Status |
|---|---|---|---|---|
4/7/2022 | Application |
Application Date | 4/7/2022 |
|---|---|
Grant Date | |
Title | |
Related Topics | |
Status | Application |
Latest Ultrasight News
Mar 1, 2023
Developed innovative guidance technology for ultrasound image acquirement Today, UltraSight, an Israeli-based digital health pioneer transforming cardiac imaging through the power of artificial intelligence, announced it has been granted a patent for real-time guidance of ultrasound devices. “Receiving a patent for real-time guidance fortifies UltraSight’s presence as a vital player in the ultrasound ecosystem and propels us forward as an industry leader,” said UltraSight CEO Davidi Vortman. “Together with our partners, The Weizmann Institute of Science and NYU Langone School of Medicine, we have built a deep technology that promises to simplify cardiac ultrasound.” UltraSight’s guidance technology aims to allow medical professionals with no prior sonography experience to accurately perform echocardiographic examinations and acquire high quality diagnostic images of the heart. The technology was developed for use at the point of care, including clinics, community hospitals, ambulances, and remote and rural settings – paving the way for more widespread detection of cardiovascular diseases and improved access to optimized cardiac care. “Today not only marks another milestone for the company, but it moves the needle forward on our mission to increase patient access to cardiac treatment and care,” said Itay Kezurer, co-founder and CTO of UltraSight. “We are now on the cusp of a future where ultrasound can be easily performed by healthcare professionals in nearly any setting.” UltraSight’s underlying AI neural network predicts the position and orientation of the probe relative to the heart, based on the ultrasound video stream, and guides the user on how to maneuver the probe to capture diagnostic quality cardiac images. The patent was granted by the U.S. Patent and Trademark Office (USPTO). UltraSight received its European patent on January 18, 2023, and last year its software was awarded a CE Mark. The guidance software is currently under FDA review. previous post
Ultrasight Frequently Asked Questions (FAQ)
When was Ultrasight founded?
Ultrasight was founded in 2018.
Where is Ultrasight's headquarters?
Ultrasight's headquarters is located at 564 1st Ave, New York.
What is Ultrasight's latest funding round?
Ultrasight's latest funding round is Series B.
How much did Ultrasight raise?
Ultrasight raised a total of $15M.
Who are the investors of Ultrasight?
Investors of Ultrasight include Weizmann Institute of Science, Yozma Group Korea, Atain Insurance, Philips Healthworks, Alpha Holdings and 3 more.
Who are Ultrasight's competitors?
Competitors of Ultrasight include Caption Health.
What products does Ultrasight offer?
Ultrasight's products include UltraSight AI Guidance.
Compare Ultrasight to Competitors
Butterfly Network operates within diagnostic and therapeutic imaging with devices, deep learning, and the cloud. Butterfly Network operates at the intersection of engineering and medicine by bringing together computer science, physics, mechanical engineering, electrical engineering, and medicine. The company was founded in 2011 and is based in Guilford, Connecticut.
Ultromics provides autonomous echocardiography analysis through AI solutions, empowering physicians to make decisions when diagnosing cardiovascular disease. Its cloud-based service, EchoGo, uses artificial intelligence to fully automate the pathway to diagnosis, providing reports for clinicians without any need for physical software on-site. The company was founded in 2017 and is based in Oxford, U.K.
DiA Imaging Analysis offers rapid, objective, and accurate Al-Based technology platforms that automatically detect the right image view and clinical abnormalities that clinicians are struggling to find visually.
EchoNous develops a product line of intelligent medical tools to assist healthcare professionals. The company's primary product, Kosmos, is an AI-assisted handheld ultrasound tool that aims to increase diagnostic confidence at the bedside by enabling any clinician to perform heart, lung, and abdominal assessments. The company was founded in 2016 and is based in Redmond, Washington.
SmartAlpha develops AI healthcare solutions for biopsy and ultrasound interpretations.
Us2.ai has developed a machine learning platform to automate the slow, manual and error-prone process of measuring and interpreting echocardiograms, or ultrasound images of the heart. The company was founded in 2017 and is based in Singapore.
Discover the right solution for your team
The CB Insights tech market intelligence platform analyzes millions of data points on vendors, products, partnerships, and patents to help your team find their next technology solution.